Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Targeted sequencing panel IDs Lynch syndrome in women with/at risk for endometrial cancer

Key clinical point: Targeted Lynch syndrome sequencing panel rapidly IDs Lynch syndrome pathogenic mutations.

Major finding: Lynch syndrome prevalence may be 6-7 times greater than the current estimate of 3% to 5%.

Study details: An analysis of a next-generation sequencing panel in 71 patients.

Disclosures: Dr. Padron reported having no relevant financial disclosures.

Citation:

REPORTING FROM ACOG 2019